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Abstract
Background: Hereditary angioedema caused by C1-inhibitor deficiency (C1-INH-HAE) is a rare, autosomal dominant
disorder. C1-INH-HAE is characterized by edema–formation, which may occur in response to stress. The individual’s
response to stress stimuli is partly genetically determined. Activation of the hypothalamic–pituitary–adrenal axis
results in the release of cortisol. In turn, the secreted gluco- and mineralocorticoids affect the metabolism, as well as
the cardiovascular and immune systems. We hypothesized that changes in serum cortisol level and polymorphisms
of the glucocorticoid receptor (GR) modify the individual sensitivity to stressor stimuli of C1-INH-HAE patients.
Results: We compared the response to stress with Rahe’s Brief Stress and Coping Inventory of 43 C1-INH-HAE
patients, 18 angioedema patients and 13 healthy controls. 139 C1-INH-HAE patients and 160 healthy controls were
genotyped for glucocorticoid receptor polymorphisms BclI, N363S and A3669G. Serum cortisol levels were
determined during attacks and during symptom-free periods in 36 C1-INH-HAE patients. The relationships between
clinical, laboratory data and GR SNPs (Single Nucleotide Polymorphisms) were assessed using ANOVA. C1-INH-HAE
patients have decreased coping capabilities compared to healthy controls. Cortisol levels were significantly higher
during attacks than in symptom-free periods (p = 0.004). The magnitude of the elevation of cortisol levels did not
show a significant correlation with any clinical or laboratory data. Among the C1-INH-HAE patients, the carriers of
the A3669G allele had significantly lower cortisol levels, and increased body mass index compared with non-carriers.
Conclusions: The higher cortisol level observed during attacks may reflect the effect of a stressful situation (such as of
the attack itself), on the patients’ neuroendocrine system. In A3669G carriers, the lower cortisol levels might reflect
altered feedback to the hypothalamic–pituitary–adrenal axis, due to decreased sensitivity to glucocorticoids.
Keywords: Hereditary angioedema, C1-inhibitor deficiency, Trigger factor, Emotional stress, Coping, Glucocorticoid
polymorphisms, Glucocorticoid sensitivity
Background
Hereditary angioedema (HAE) with C1-inhibitor deficiency
(C1-INH-HAE) is a rare, autosomal dominant disorder,
which belongs to bradykinin-mediated angioedemas [1].
The deficiency of a serine protease protein C1-inhibitor
(C1-INH) results in the activation of four plasma cascade
systems (fibrinolytic, coagulation, kinin, and complement
cascades), and this leads to the release of bradykinin from
high-molecular-weight kininogen. Bradykinin, a vasoactive
mediator, enhances capillary permeability. As a result,
plasma leaks from the intravascular compartment into the
extracellular space, leading to edema formation [2]. The ep-
isodes of angioedema may involve the subcutis and/or the
submucosa in patients with HAE. Angioedema attacks may
cause severe abdominal pain, which resembles that occur-
ring in an abdominal emergency, or upper airway edema,
which can lead to asphyxiation [3].
In general, C1-INH-HAE first occurs during the first
decade of life [4, 5]. Although a consensus parameter de-
fining the severity of HAE is lacking, it is characterized
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by the frequency of edematous attacks, subjective de-
scribed attack severity and the need of on demand
C1-INH substitution.
The factors, which may trigger an attack, include infec-
tions, emotional stress, physical exertion, trauma, invasive
medical procedures, menstruation, and contraceptive use,
as well as treatment with certain medications (i.e. ACE-
inhibitors). In our recent study, we found that emotional
stress is the most common trigger factor of attacks [6].
Chronic stress as a general risk factor for the develop-
ment of several diseases; it can also modify disease ac-
tivity [7–10].
Stressor stimuli activate the hypothalamic–pituitary–
adrenal (HPA) axis, and result in the release of mineralo-
and glucocorticoids (GCs). The sustained elevation of
glucocorticoid (GC) levels has been associated with hyper-
tension, weight gain, glucose intolerance, and hypertrigly-
ceridaemia. GCs exert their diverse actions through the
GC receptor (GR), which is ubiquitously expressed in
many tissues and cell types [11]. Differences in individ-
ual glucocorticoid sensitivity may influence stress re-
activity. Furthermore, altered glucocorticoid sensitivity
has been shown to modify the manifestations of several
diseases [12–14]. A few polymorphisms in the GR gene
are known to modify glucocorticoid sensitivity. The BclI
(rs41423247), a restriction fragment length polymorphism
(RFLP), results from an intronic region (C/G) nucleotide
substitution associated with increased glucocorticoid
sensitivity, as well as with increased abdominal obesity,
greater body mass index (BMI), decreased insulin sensi-
tivity and dyslipidemia [15, 16]. The BclI polymorphism
has been implicated in the pathogenesis or onset of vari-
ous diseases [12–14, 17, 18]. In the central nervous sys-
tem, it has been linked to mood disorders and to the
responsiveness of the HPA axis [19, 20].
The N363S (rs6195) polymorphism in exon 2 of the
GR gene, the (A/G) substitution causes an asparagine-to-
serine change, associated with enhanced glucocorticoid
sensitivity [21]. The results regarding the relationship of
autoimmune diseases and carrier status are controversial
[11]. This polymorphism has been described to modify
disease symptoms patients with congenital adrenal hyper-
plasia (CAH), and may be involved in the pathogenesis of
bilateral adrenal adenomas [22, 23]. The A3669G (GR-9ß,
rs6198) polymorphism is located in the 3’ untranslated
region of the GR gene. The (A/G) nucleotide substitu-
tion destabilizes the mRNA and causes a shift to the
stabilization of the GRß (glucocorticoid receptor beta)
splicing variant. The GRß isoform exerts a dominant,
negative activity on the GRα (glucocorticoid receptor
alpha) function, and the altered GRα/GRß ratio may lead
to relative glucocorticoid resistance [24]. The A3669G
polymorphism has been linked to a more active immune
system [11], and to the development of rheumatoid
arthritis [25]. The A3669G SNP was also attributed a role
to bipolar diseases and depressive disorders [26, 27].
In this study, we investigated whether the clinical
manifestations of C1-INH-HAE may be different in
carriers of the three single nucleotide polymorphisms
(SNP) of the GR gene because these SNPs have been
associated with altered GC sensitivity. We hypothesized
that they might have a role in mediating the effects of
emotional stress on edema formation in patients with
C1-INH-HAE, during attacks in the first place.
Methods
Patients
C1-INH-HAE group: All subjects had been diagnosed
and receiving regular follow-up care at the Hungarian
Angioedema Center. In each patient, we established the
diagnosis of C1-INH-HAE according to standard clinical
and laboratory criteria (positive family history, clinical
symptoms of angioedema, low functional C1-INH level,
low C4, normal C1q). During the scheduled visits, the
time of occurrence, location, and severity of the edema-
tous episodes were recorded along with the on demand
therapy (e.g. C1-INH concentrate, icatibant) administered
to relieve the attack. All these information was taken into
account to modify long-term prophylaxis as necessary.
Further, the concomitant medications taken on a regular
basis and accompanying disorders were recorded, and the
patients’ body height and weight were checked on these
occasions.
The angioedema group comprised patients with angio-
edema, a negative family history, and normal C4, C1q,
C1-INH antigen levels and functional activity.
Healthy controls: All had been referred for routine med-
ical check-up, and volunteered for the study by giving
informed consent. The healthy controls did not have
any known disease (C1-INH deficiency was excluded by
complement testing).
The study was approved by the institutional review
board of Semmelweis University of Budapest. Informed
consent was obtained from the subjects in accordance
with the Declaration of Helsinki.
Evaluation of the response to stress
The response of the subjects to stress was measured
with Rahe’s Brief Stress and Coping Inventory [28]. This
instrument is used to categorize the population tested
into four subsets, according to subjectively experienced
stress level and coping capabilities. The test was completed
by 43 patients diagnosed with C1-INH-HAE (mean age:
38.00 years, SD: 16.87 years; 22 females and 21 males), by
18 patients showing angioedematosus symptoms without
C1-INH deficiency (mean age: 48.00 years, SD: 19.56 years,
15 females and 3 males), and 13 healthy controls. Statistical
analysis was performed with the Kruskal-Wallis test.
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Genotyping
We genotyped 139 patients diagnosed with C1-INH-
HAE (mean age 38.9 years, range: 5–84 years, 76 females
and 63 males). A Hungarian control population consisting
of 160 healthy individuals was used for comparison as
regards the prevalence of GR SNPs. Total genomic DNA
was isolated from peripheral blood with a commercially
available DNA isolation kit (QIAmp DNA Blood Mini Kit
(Qiagen), according to the manufacturer’s instructions.
The BclI and N363S polymorphisms were detected with
allele-specific polymerase chain reaction (PCR), as de-
scribed previously [14, 29].
The A3669G polymorphism was measured with a pre-
designed TaqMan SNP Assay (C_8951023_10) (Applied
Biosystems, LifeTechnologies), by real-time PCR, accord-
ing to the recommended protocol, on a 7500 Fast PCR
System (Applied Biosystems, LifeTechnologies).
Hormonal evaluation
Blood samples were collected from patients hospitalized
(to the Semmelweis University, 3rd Department of Internal
Medicine) for an edematous attack. During the attack-free
period, morning fasting blood samples were obtained from
these patients between 8:00 and 11:00 AM at the Hungar-
ian Angioedema Center of the 3rd Department of Semmel-
weis University. Blood cortisol levels were measured during
edematous attacks in 36 C1-INH-HAE patients. The blood
samples were obtained by antecubital venipuncture. The
samples were stored refrigerated (at −70 °C) until the meas-
urement of serum cortisol levels and of C1-INH activity.
Total cortisol levels in the plasma were determined by elec-
trochemiluminescence immunoassay (Elecsys Immunoana-
lyser System, Roche). The functional level of the C1-
inhibitor was determined with an enzyme immunoassay
kit (Quidel, USA).
Statistical analysis
The allele frequencies of GR polymorphisms in C1-INH-
HAE patients and in healthy controls were compared with
Pearson’s χ2 or Fisher’s exact test. The Hardy-Weinberg
equilibrium was calculated for all polymorphisms. The as-
sociations between carrier status for polymorphisms
and clinical or hormonal data were analyzed with
ANOVA, and with the Kruskal-Wallis, or t-tests. We
also performed statistical power analysis with a tool
available online (https://www.dssresearch.com/Knowledge
Center/toolkitcalculators/statisticalpowercalculators.aspx).
Statistical power over 80%, and a p-value less than 0.05
were considered significant.
Results
The evaluation of response to stress
We did not find significant differences among the stress
responses as measured with the Rahe’s Brief Stress and
Coping Inventory tests in patients diagnosed with C1-
INH-HAE, in angioedematous patients (without C1-INH
deficiency), and healthy controls, using the Kruskal-Wallis
one-way analysis of variance test (p = 0.1725). Reported
coping capabilities differed significantly among the study
populations (p = 0.0027). See Fig. 1.
Hormonal evaluation
Serum total cortisol levels were significantly (p = 0.004)
different in samples obtained from the same patient dur-
ing an edematous attack, or in an attack-free period
(Wilcoxon matched pairs test) (Fig. 2). In particular, mean
total cortisol level in the serum was 9.679 ug/dl (SD 4.68)
during an attack-free period, and 14.89 ug/dl (SD 11.58)
during an attack. Similarly, C1-INH activity was signifi-
cantly (p < 0.0001) higher during attacks. While mean
C1-INH activity was 22.88% (SD 18.98) in attack-free
periods, it increased to 48.18% (SD 24.81) during attacks
(Fig. 2). We did not detect a significant correlation be-
tween the changes of cortisol level and of C1-INH activity.
GR polymorphisms
There was no difference between the two populations
as regards the allele frequencies of the N363S, BclI
and A3669G polymorphisms (Table 1). The A3669G
homozygous carrier state was significantly lower in the
C1-INH-HAE group compared to healthy controls
(Statistical power: 71,4%).
The association between A3669G polymorphism and
cortisol levels in C1-INH-HAE patients
We grouped A3669G heterozygous and homozygous pa-
tients as A3669G carriers because of the low number of
homozygous patients. Mean serum cortisol level was
lower in carriers of the A3669G polymorphism compared
to non-carriers (7.3 ± 3.3 vs. 10.9 ± 4.81, p = 0.0173; statis-
tical power: 99.9%) (Fig. 3). Moreover the cortisol levels
were lower during attack also in the carrier group; how-
ever, this difference did not reach significance (p = 0.0653).
In four patients, the attack was localized to the upper
airway mucosa (pharynx and larynx) and caused obstruc-
tion. Such a symptom is a rather intense stressor and
hence it may mask the impact of the polymorphism.
Therefore, we re-analyzed cortisol levels without the re-
sults of these patients. In A3669G carriers, lower basal
cortisol levels remained significant (6.76 ± 3.14 vs. 10.96 ±
3.46, p = 0.013, statistical power: 92.9%). Meanwhile the
difference between the steroid levels measured in the two
groups during attacks had become significant (8.22 ± 2.64
vs. 18.34 ± 13.0394, p = 0.0148, statistical power 91.7%).
Based on the previously mentioned hypothesis, patients
who experienced severe attacks were also disregarded,
but the difference between carrier and non-carrier
groups nevertheless remained significant. Along similar
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considerations, we did not take into account the attacks
rated severe by the patients themselves. Notwithstand-
ing this, we found a significant difference between the
two groups (8.94 ± 2.3 vs. 16.91 ± 9.4, p = 0.0204, statis-
tical power 85.8%) (Fig. 3).
The change from baseline of the cortisol levels measured
during edematous attacks was smaller in the A3669G car-
rier group compared with non-carriers, but this difference
did not reach significance (1.00 ± 3.04 vs. 6.85 ± 14.40,
p = 0.057).
We also found that A3669G carriers had significantly
higher BMI values, whereas hypertension was more com-
mon in the group of BclI homozygous carriers, compared
with non-carriers (Table 2). We did not find any associ-
ation between the investigated polymorphisms and any
other clinical variable (the initial onset of attacks, the fre-
quency of edematous episodes, C1-INH consumption).
There were no gender-specific associations between car-
rier status and hormonal levels.
Discussion
In this study, we showed that stress response is intact in
patients with C1-INH-HAE, although the reported cop-
ing capabilities differed significantly among the subsets
of the study population. The lifelong management of any
chronic and/or life-threatening disease requires consid-
erable mental strength [30]. This might have contributed
to the C1-INH-HAE-patients’ propensity for depression.
The latter we have investigated in a previous study, the
findings of which are in agreement with those published
by Fouche et al. [31].
During stress, activation of the HPA axis results in the
elevation of stress hormone levels: the serum concentra-
tions of cortisol and of catecholamines reflect the activa-
tion of HPA axis. In our patient population, basal
cortisol level was lower in C1-INH-HAE patients carry-
ing the A3669G polymorphism. This SNP increases the
stability of the splicing variant GRß [24], which inhibits
the function of GRα. Our results are consistent with
Fig. 1 The scores achieved by the three subsets of our study population on Rahe’s Brief Stress & Coping Inventory. The scores achieved by the
C1-INH-HAE patients, angioedema patients and healthy controls on Rahe’s Brief Stress & Coping Inventory
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those reported by van Schoor et al., who found reduced
serum fasting cortisol levels in female carriers of the
A3669G polymorphism, compared with homozygous
carriers of the wild type [17]. In stressful situations, the
elevation of the cortisol levels of C1-INH-HAE patients
during an edematous attack might result from the acti-
vation of HPA axis. This offers a possible, alternative ex-
planation for the increase of white blood cell count
during attacks described previously by our study group
[32], which previously has been attributed to haemocon-
centration. Remarkably, during non-severe attacks, car-
riers of the A3669G polymorphism had lower cortisol
levels, and exhibited a smaller elevation of serum cortisol
level than non-carriers. This suggests blunted responsive-
ness of the HPA axis – in agreement with the findings by
Kumsta et al. These authors reported higher awakening
Table 1 Minor allele frequency and carrier state for GR polymorphisms in C1-INH-HAE patients and in healthy controls
Polymorphism C1-INH- HAE Healthy control group p value
N = 139 N = 160
N363S
Minor allele frequency 0.05 0.031 0.78
Heterozygous carriers (+/−) 13 (9.3%) 10 (6.3%) 0.77
Homozygous carriers (+/+) - - -
Non-carriers 126 (90.7%) (96,7%) (90.7%) 150 (93.7%) 0.77
BclI
Minor allele frequency 0.36 0.35 0.87
Heterozygous carriers (+/−) 53 (38.1%) 82 (51.3%) 0.08
Homozygous carriers (+/+) 24 (17.3%) 16 (10%) 0.24
Non-carriers 62 (44.6%) 62 (38.7%) 0.72
A3669G
Minor allele frequency 0.15 0.22 0.11
Heterozygous carriers (+/−) 39 (28.1%) 48 (30%) 0.99
Homozygous carriers (+/+) 2 (1.4%) 12 (7.5%) 0.04
Non-carriers 98 (70.5%) 100 (62.5%) 0.42
Minor allele frequency and carrier state for GR polymorphisms in C1-INH-HAE patients and in healthy controls. The p value was adjusted with Bonferroni correction.
Statistically significant values are marked by bold typeset
Fig. 2 Serum total cortisol levels a and C1-INH activity b in the same patients between, or during edematous attacks. Serum total cortisol levels
a and C1-INH b activity in blood samples obtained from the same patients between, or during edematous attacks. The reference range is marked
by grey shading
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ACTH and salivary cortisol levels after dexamethasone
administration in male A3669G carriers [33]. Remarkably,
they also found that healthy male carriers of the A3669G
minor allele showed the highest ACTH and cortisol levels
in response to social stress; however this observation
was not confirmed by a subsequent study in adolescents
[33, 34]. These somewhat controversial results on the
association between polymorphisms and cortisol levels
under stress may be related to the differences in the study
populations and stressors. Nevertheless, there is strong
evidence that polymorphisms in the GR gene gene thor-
ough the negative feed-back effect of cortisol on the
HPA axis may modify the responsiveness of the HPA,
along with individual stress responses [19]. Together, these
data confirm that the A3669G carrier state is associated
with relative glucocorticoid resistance during activation of
the HPA axis. In C1-INH-HAE patients, edematous at-
tacks are a chronic source of stress, permanently elevated
Table 2 Clinical and metabolic parameters of C1-INH-HAE patients in relation to the investigated GR polymorphisms
N363S BclI A3669G
Non-carriers
n = 94
Carriers
n = 12
Non-carriers
n = 51
Heterozygous
carriers n = 39
Homozygous
carriers n = 16
Non-carriers
n = 75
Carriers
n = 31
(54f + 40 m) (5f + 7 m) (31f + 20 m) (20f + 19 m) (8f + 8 m) (40f + 35 m) (19f + 12 m)
Age (mean ± SD) 39.88 ± 18.04 32.54 ± 11.88 35.02 ± 17.84 42.33 ± 15.99 43.79 ± 18.68 39.4 ± 18.2 39.2 ± 15.1
Onset of the initial attack
(age) (mean ± SD)
12.23 ± 9.51 8.08 ± 5.68 11.71 ± 11.34 11.18 ± 6.58 13.3 ± 7.9 11.9 ± 8.8 11.2 ± 10.2
Number of attacks /year
(mean ± SD)
8.4 ± 11.2 11.9 ± 13.3 10.2 ± 13.6 7.4 ± 9.9 7.5 ± 6.3 8.4 ± 12.4 10 ± 8.9
Average C1-INH consumption
(amp/year) (mean ± SD)
1.6 ± 3.5 2.4 ± 3.9 1.8 ± 4.0 1.6 ± 3.1 1.6 ± 3.2 2.2 ± 3.5 1.5 ± 3.6
BMI (kg/m2) (mean ± SD) 24.99 ± 5.55 27.29 ± 3.91 24.17 ± 5.56 25.99 ± 5.21 26.87 ± 5.11 24.2 ± 5.03° 28.4 ± 4.8°
Prevalence of hypertension (%) 18.1 8.33 7.80* 17.95 37.5* 17.3 16.1
Prevalence of diabetes (%) 5.3 0% 3.9 5.13 6.2 5.3 3.2
Clinical and metabolic parameters of C1-INH-HAE patients in relation to the investigated GR polymorphisms. Results are mean ± SD. Statistically significant values
are marked by bold typeset. °p < 0.0001 statistical power 98.2%, *p = 0.0126, statistical power 84.6%
Abbreviations: f female, m male.
Fig. 3 Cortisol levels in carriers and non-carriers of the A3669G polymorphism. Cortisol levels in carriers and non-carriers of the A3669G polymorphism.
a: The entire patient population during attack-free period. b: Cortisol levels during attacks without upper airway edema. c: Cortisol levels during
non-severe attacks
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glucocorticoid levels due to the chronic activation of
the HPA axis may lead to the development stress related
disorders, eg. dysfunction of the immune system, hyper-
tension, diabetes and adverse cardiovascular events. Hypo-
thetically alterations of HPA axis responsivity may
influence these unfavourable outcomes of chronic stress,
however the impact of GR polymorphisms on stress re-
sponse needs further examinations, including the meas-
urement of ACTH and prospective follow up of patients.
Stress responsiveness, and activation of the HPA axis
are known to differ between the sexes [35]. Furthermore,
Kumsta et al. found gender-specific differences in the
modulation of the responsiveness of the HPA axis by GR
polymorphisms [33]. However, we could not observe
sex-specific associations in our study.
We found that the allelic frequencies of the investigated
three polymorphisms in the GR gene (BclI, N363S,
A3669G) did not differ significantly between C1-INH-HAE
patients and healthy controls. Although the A3669G
homozygous carrier state was significantly lower in C1-
INH-HAE patients, the low statistical power rather in-
dicate this finding a bias.
We could not detect any relationship between the in-
vestigated GR polymorphisms and the severity of edema-
tous attacks (as regards attack frequency, and C1-INH
consumption) in C1-INH-HAE patients. Furthermore,
the during-attack elevation of C1-INH functional levels
did not exhibit any correlation with cortisol levels.
These data suggest that glucocorticoids are not in-
volved in the mechanism of edema formation due to
C1-INH deficiency.
Glucocorticoids play an important role in the regula-
tion of metabolism. Polymorphisms in the GR gene have
been previously linked with various clinical parameters
[11]. In our C1-INH-HAE patients, the prevalence of
hypertension was higher in carriers of the polymorphic
BclI allele. BclI polymorphism has been implied with an
increased response to glucocorticoids. Our results are in
accord with earlier observations regarding the unfavorable
effect of BclI polymorphisms on blood pressure in differ-
ent patient populations [36–38]. Interestingly, carriers of
the A3669G allele had increased BMI. This is rather intri-
guing, as lower serum cortisol levels are expected to pro-
tect the carriers against weight gain. This finding suggests
a poor correlation among blood cortisol levels and
metabolic parameters.
Conclusions
In summary, the examined polymorphisms of the GR
gene are most likely not involved in the pathomechanism
of C1-INH HAE. Minor allele carriers of the A3669G
polymorphism have lower cortisol levels both in attack
free periods, and during attacks. Possibly, this reflects a
relative resistance against glucocorticoids on the level of
the HPA axis. In contrast with this observation, we could
not find any association between carrier state and disease
severity in HAE patients. Further hormonal evaluations
are necessary to clarify the impact of GR polymorphisms
on the responsiveness of the HPA axis in C1-INH-HAE
patients.
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